Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47804
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYıldız, Fatih-
dc.contributor.authorDemirci, Umut-
dc.contributor.authorKüçükard, Ahmet-
dc.contributor.authorBüyükşimsek, Mahmut-
dc.contributor.authorSakalar,Teoman-
dc.contributor.authorTopçu, Turkan-
dc.contributor.authorAslan, Ferit-
dc.contributor.authorTufan, Gülnihal-
dc.contributor.authorAydın, Övgü-
dc.contributor.authorTurna, Hande-
dc.contributor.authorBabacan, Nalan-
dc.contributor.authorBaşoğlu, Tuğba-
dc.contributor.authorKurt, Bediz-
dc.contributor.authorYıldız, Birol-
dc.contributor.authorEren, Tülay-
dc.contributor.authorDemiray, Atike-
dc.contributor.authorGümüşay, Özge-
dc.contributor.authorArslan, Çağatay-
dc.contributor.authorÖzdemir, Nuriye-
dc.contributor.authorÜrün, Yüksel-
dc.contributor.authorBaykara, Meltem-
dc.contributor.authorTuran, Nedim-
dc.contributor.authorUysal, Mükremin-
dc.contributor.authorBilici, Ahmet-
dc.contributor.authorKavgacı, Halil-
dc.contributor.authorCicin, İrfan-
dc.contributor.authorKılıçkap, Saadettin-
dc.contributor.authorPaydaş, Semra-
dc.date.accessioned2023-01-09T21:30:08Z-
dc.date.available2023-01-09T21:30:08Z-
dc.date.issued2021-
dc.identifier.issn0973-1482-
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT-950-19-
dc.identifier.urihttps://hdl.handle.net/11499/47804-
dc.description.abstractBackground: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and Methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence. © 2021 Wolters Kluwer Medknow Publications. All rights reserved.en_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCK20en_US
dc.subjectmerkel cell carcinomaen_US
dc.subjectneuroendocrin carcinomaen_US
dc.subjectskin carcinomaen_US
dc.subjectavelumaben_US
dc.subjectcarboplatinen_US
dc.subjectcisplatinen_US
dc.subjectcyclophosphamideen_US
dc.subjectcytokeratin 20en_US
dc.subjectdoxorubicinen_US
dc.subjectetoposideen_US
dc.subjectvincristineen_US
dc.subjectadjuvant radiotherapyen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectArticleen_US
dc.subjectcancer adjuvant therapyen_US
dc.subjectcancer combination chemotherapyen_US
dc.subjectcancer radiotherapyen_US
dc.subjectcancer recurrenceen_US
dc.subjectcancer stagingen_US
dc.subjectcancer survivalen_US
dc.subjectchemoradiotherapyen_US
dc.subjectclinical evaluationen_US
dc.subjectdisease free survivalen_US
dc.subjectdistant metastasisen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjecthistopathologyen_US
dc.subjecthumanen_US
dc.subjectimmunohistochemistryen_US
dc.subjectimmunosuppressive treatmenten_US
dc.subjectlimb tumoren_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmerkel cell carcinomaen_US
dc.subjectmulticenter studyen_US
dc.subjectoverall survivalen_US
dc.subjectprogression free survivalen_US
dc.subjectretrospective studyen_US
dc.subjecttreatment outcomeen_US
dc.subjectTurkey (republic)en_US
dc.subjectvery elderlyen_US
dc.subjectaftercareen_US
dc.subjectclinical trialen_US
dc.subjectepidemiologyen_US
dc.subjectincidenceen_US
dc.subjectmerkel cell carcinomaen_US
dc.subjectmiddle ageden_US
dc.subjectmortalityen_US
dc.subjectprevention and controlen_US
dc.subjectproceduresen_US
dc.subjectskin tumoren_US
dc.subjecttumor recurrenceen_US
dc.subjectturkey (bird)en_US
dc.subjectAdulten_US
dc.subjectAftercareen_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectCarcinoma, Merkel Cellen_US
dc.subjectChemoradiotherapyen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectIncidenceen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectNeoplasm Stagingen_US
dc.subjectProgression-Free Survivalen_US
dc.subjectRetrospective Studiesen_US
dc.subjectSkin Neoplasmsen_US
dc.subjectTurkeyen_US
dc.titleMerkel cell carcinoma in Turkey: A multicentric studyen_US
dc.typeArticleen_US
dc.identifier.volume17en_US
dc.identifier.issue6en_US
dc.identifier.startpage1525en_US
dc.identifier.endpage1529en_US
dc.identifier.doi10.4103/jcrt.JCRT-950-19-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57211777547-
dc.authorscopusid26026850900-
dc.authorscopusid57193238894-
dc.authorscopusid57202022380-
dc.authorscopusid57204201984-
dc.authorscopusid56723995200-
dc.authorscopusid57217031807-
dc.identifier.pmid34916389en_US
dc.identifier.scopus2-s2.0-85121898572en_US
dc.identifier.scopusqualityQ3-
item.languageiso639-1en-
item.openairetypeArticle-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
Show simple item record



CORE Recommender

Page view(s)

32
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.